Israel Medical Association Journal

Background: Flumazenil has been available since 1991 for the treatment of acute benzodiazepine overdose, yet many physicians remain reluctant to use it.

Objectives: To evaluate the frequency of flumazenil use for benzodiazepine overdose at a large, urban, tertiary care center. To assess its effectiveness and associated adverse events.

Methods: The study was conducted in an emergency department with approximately 220,000 annual visits. Medical records of patients who received a medical toxicology consultation and were treated with flumazenil between 1 January 2019, and 31 December 2023 were reviewed. Data collected included patient demographics, medical history, substances involved, presence of seizures, indications for flumazenil use, clinical response, and adverse effects.

Results: Of 263 patients evaluated for suspected benzodiazepine overdose and referred to medical toxicology, 79 received flumazenil and comprised the study cohort. Among them, 64 cases involved intentional overdose. Indications for flumazenil administration included severe overdose with impaired consciousness and ventilatory failure (37 patients) or without ventilatory failure (42 patients). Co-ingestion of tricyclic antidepressants was documented in 4 patients and other antidepressants or antipsychotics in 35. Clinical improvement, including enhanced consciousness and/or reduced need for mechanical ventilation, was observed in all 79 patients. No adverse effects, including seizures, were reported.

Conclusions: In this retrospective cohort, flumazenil was administered without serious adverse events and was associated with improved alertness and ventilation. While caution is required, particularly in mixed overdoses, flumazenil may have a role in managing benzodiazepine-induced respiratory depression when guided by toxicology consultation.

Background: Opioid-base sedation is considered the first line choice in ventilated patients in intensive care units (ICU). Few studies have examined sedation in ventilated patients outside the ICU. A pilot program was initiated in the internal medicine ward A at Meir Hospital in Kfar Saba, Israel. A new sedation protocol was implemented for opioid-based versus benzodiazepine-based sedation in ventilated patients.

Objectives: To compare the rates and intensity of delirium between patients who received opioid-based sedation vs. benzodiazepine-based sedation. To compare parameters related to morbidity and mortality.

Methods: We conducted a retrospective before-after intervention study based on data collection. Patients who were admitted to the internal medicine ward A from January 2020 to January 2021 and required sedation and ventilation were included. Demographic data, medical history data, admission data, Richmond Agitation and Sedation Scale scores, hemodynamic parameters, reports of falls and self-harm, and data regarding unplanned extubation were collected, as well as the need for additional sedative drugs.

Results: Chronic hypertension was more common in the opioid group. Delirium intensity tended to be higher in the benzodiazepine group. The number of ventilation days was significantly higher in the benzodiazepine group, as was the number of times adjuvant sedation was required.

Conclusions: Opioid-based sedation outside the ICU was associated with shorter ventilation days, tendency toward lower intensity of delirium, and reduction in requirement of adjuvant sedative drugs compared to benzodiazepine-based sedation. Further studies are required to confirm the findings.